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August 2010530 Abstractsjust Coumadin resulted in 32% incidence (12 of 38, P  .008) of endoleak.
Dual AP therapy had a 12% rate (3 of 25, P  .427). Single AP therapy
resulted in a 16% incidence (34 of 225, P  .29). Patients with a normal
coagulation and platelet profile had a 13% incidence (11 of 82) of endoleak.
There was a 9.6% need for postoperative reinterventions for all comers. For
patients on a combination of AP and Coumadin, there was a 35% need for
postoperative intervention (P  .001) compared with 16% if just on Cou-
madin alone (P .044). This decreased to 13% for those on dual AP agents
(P  .06) and 7% for both single AP (P  .396) or no agents.
Conclusions:Combination AP and Coumadin therapy has the highest
risk for the development of endoleak. Coumadin alone was also found to be
a significant risk factor. Dual AP therapy, single AP therapy, and no agents
were equivalent. In addition, the combination of AP and Coumadin resulted
in a high incidence of post-EVAR reintervention. These patients should be
monitored closely after endovascular aortic aneurysm repair.
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Objective: AAA is a common and potentially lethal condition. Endo-
vascular aneurysm repair (EVAR) reduces morbidity but is less durable than
open repair secondary to continued remodeling of the diseased aorta. Local
delivery of compounds inhibiting degeneration of the neck and promoting
sac regression may stabilize endografts and improve durability. Our objec-
tive was to determine if HMG-CoA reductase inhibitors (statins) and
angiotensin receptor blockers (ARBs) are appropriate candidates for drug-
device hybrid therapies based on their efficacy in experimental AAA attenu-
ation.
Methods: Apo E/ male mice were infused with angiotensin (Ang)
II (1.0 mg/kg/min) via minipumps. Statin (n  6; 40 mg/kg/d), ARB1
(n 6; 50 mg/kg/d), and ARB2 (n 6; 10 mg/kg/d) were administered
via drinking water (statin) or chow (ARBs) and compared with control mice
treated with Ang II alone (n  6). Aortic diameter was serially determined
with ultrasonography.Mice were sacrificed 28 days after pump implantation.
Immunohistochemistry was performed to evaluate aortic elastin preserva-
tion, medial SMC maintenance, and mural inflammation and neovascular-
ization. Patterns of gene expression were determined via qPCR. Serum drug
concentrations were quantified on the day of sacrifice.
Results:Multiple dissections (n 4) and ruptures (n 3) occurred in
control animals. None were observed in statin- or ARB-treated mice. Statin
(1.30 0.19mm), ARB1 (1.17 0.12mm), and ARB2 (1.13 0.05mm)
treatment significantly attenuated aortic dilatation compared with control
(1.69  0.46 mm; P  .05; Fig). Histologic, biomarker, and serologic
analyses were not complete at the time of submission.
Conclusions: Statins and ARBs inhibit experimental AAA progression.
Further histologic and biomarker analysis is forthcoming and will aid in the
determination of mechanisms of statin and ARB aneurysm inhibition. Local
delivery of these compounds may limit endograft failure via inhibition of
aortic remodeling following AAA exclusion.
Fig. Comparison of baseline and terminal aortic diameters, *P 
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Objectives: Patients with pancreatic tumors may have portal vein (PV)
and/or superior mesenteric vein (SMV) invasion. In such cases, lower
extremity veins can provide an autogenous conduit for PV/SMV recon-
struction. Little data exist, however, describing the technique of PV/SMV
reconstruction, the patency of such reconstructions, and the morbidity of
using lower extremity veins for PV/SMV reconstruction during pancreati-
coduodenectomy.
Methods: Thirty-four patients (mean age, 62.6 years) underwent
PV/SMV reconstruction during pancreaticoduodenectomy using lower
extremity vein. Saphenous vein was preferred for patching and femoral vein
for replacement.We analyzed preoperative imaging, reconstruction patency,
vein harvest morbidity, and late mortality.
Results: All 34 patients had preoperative CT imaging and/or
endoscopic ultrasound (EUS) imaging. Of the 34 patients, 14 had
evidence of PV/SMV invasion on CT or EUS, 14 did not, and 6 studies
were indeterminate. Twenty-five patients had follow-up imaging, and 22
(88%) had patent reconstructions. Fifteen patients had PV/SMV replace-
ment using femoral vein. Of these 15 patients, 7 had minor postoperative
lower extremity edema that resolved over time, 5 had wound complica-
tions from the femoral vein harvest site, 3 of which required minor
operative procedures for treatment. Fifteen patients had PV/SMV patch-
ing with greater saphenous vein, none had postoperative wound prob-
lems, and one had minimal postoperative lower extremity edema. Four
patients had PV/SMV patching using femoral vein, none had postoper-
ative wound problems, and one had minimal postoperative lower extrem-
ity edema. Compared with patients undergoing pancreaticoduodenec-
tomy without PV/SMV reconstruction, Kaplan-Meier analysis showed
there was no difference in late mortality.
Conclusions: Preoperative imaging may fail to detect PV/SMV in-
volvement in patients undergoing pancreaticoduodenectomy. PV/SMV
reconstruction with leg vein provides good patency with minimal postoper-
ative lower extremity complications and no increase in late mortality. The
lower extremities should be routinely included in the operative field of
patients undergoing pancreaticoduodenectomy.
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Objective: Resection of the pancreatic mass is the only curative option
for pancreatic cancer. Tumors that invade the nearby vasculature are deemed
unresectable. By utilizing revascularization and bypass techniques, we re-
sected pancreatic lesions with vascular invasion to improve survival in this
patient population.
Methods: Patients who presented to a high-volume, tertiary referral
center with unresectable pancreatic lesions due to vascular invasion were
evaluated by the surgical oncology and vascular teams. If both teams
found revascularization and vascular repair options were available to the
patient, a pancreatic resection was performed by the surgical oncology
team with revascularization and repair performed by vascular surgery.
Patients were followed-up by both surgical teams while in the hospital
and as outpatients.
Results: Seventeen patients (23.5% females) underwent pancreatic
resection with revascularization or vascular repair between August 2005 and
May 2009. The average age was 60.5. Average pancreatic mass size was 4.6
cm. The most common vessels requiring repair or revascularization were the
superior mesenteric and portal veins. (Two patients required SMA revascu-
larization, and one patient required right hepatic artery repair.) A pylorus-
sparing pancreaticoduodenectomy was done in 71% of patients; the remain-
der underwent distal pancreatectomy and splenectomy. All operations were
performed open. Vessels were reconstructed with cyropreserved vein (18%)
or autologous vein graft. There were no postoperative deaths. Two patients
(12%) returned to the operating room within 24 hours for a complication
related to the vascular repair, both of which were treated successfully.
Adenocarcinoma comprised 65% of lesions, and the remaining were neu-
roendocrine tumors. At this time, 82% of the patients are alive (follow-up
range, 4-48 months).
Conclusions: Planned en bloc pancreatic resection with direct revas-
cularization and/or vascular repair for traditionally unresectable lesions is a
feasible option in a high-volume center. This requires preoperative planning
and a multidisciplinary effort. Long-term studies are required to determine
the impact on patient survival, which initially appears favorable compared
with historic controls.
